I
Ingeborg Stalmans
Researcher at Katholieke Universiteit Leuven
Publications - 230
Citations - 7964
Ingeborg Stalmans is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Glaucoma & Intraocular pressure. The author has an hindex of 36, co-authored 203 publications receiving 6782 citations. Previous affiliations of Ingeborg Stalmans include Universitaire Ziekenhuizen Leuven.
Papers
More filters
Journal ArticleDOI
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
Peter Carmeliet,Lieve Moons,Aernout Luttun,Valeria Vincenti,Veerle Compernolle,Maria De Mol,Yan Wu,Françoise Bono,Laetitia Devy,Heike Beck,Dimitri Scholz,Till Acker,Tina DiPalma,Mieke Dewerchin,Agnès Noël,Ingeborg Stalmans,Adriano Barra,S. Blacher,Thierry VandenDriessche,Annica Pontén,Ulf Eriksson,Karl H. Plate,Jean-Michel Foidart,Wolfgang Schaper,D. Stephen Charnock-Jones,Daniel J. Hicklin,Jean-Marc Herbert,Desire Collen,M. Graziella Persico +28 more
TL;DR: It is reported that embryonic angiogenesis in mice was not affected by deficiency of PlGF, andTransplantation of wild-type bone marrow rescued the impairedAngiogenesis and collateral growth in Pgf−/− mice, indicating that PlGF might have contributed to vessel growth in the adult by mobilizing bone-marrow–derived cells.
Journal ArticleDOI
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.
Peter Carmeliet,Yin-Shan Ng,Dieter Nuyens,Gregor Theilmeier,Koen Brusselmans,Ivo Cornelissen,Elisabeth Ehler,Vijay V. Kakkar,Ingeborg Stalmans,Virginie Mattot,Jean Claude Perriard,Mieke Dewerchin,Willem Flameng,Andras Nagy,Florea Lupu,Lieve Moons,Desire Collen,Patricia A. D'Amore,David T. Shima +18 more
TL;DR: Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms V EGF 164 and VEGF 188 is observed.
Journal ArticleDOI
VEGF: a modifier of the del22q11 (DiGeorge) syndrome?
Ingeborg Stalmans,Diether Lambrechts,Frederik De Smet,Sandra Jansen,Jian Wang,Sunit Maity,Paige L. Kneer,Maren von der Ohe,Ann Swillen,Christa Maes,Marc Gewillig,Daniel G. M. Molin,Peter Hellings,Thurid Boetel,Maartin Haardt,Veerle Compernolle,Mieke Dewerchin,Stéphane Plaisance,Robert Vlietinck,Robert Vlietinck,Beverly S. Emanuel,Adriana C. Gittenberger-de Groot,Peter J. Scambler,Bernice E. Morrow,Deborah A Driscol,Lieve Moons,Camila V. Esguerra,Geert Carmeliet,Annett Behn-Krappa,Koenraad Devriendt,Desire Collen,Simon J. Conway,Peter Carmeliet +32 more
TL;DR: It is reported that absence of the Vegf164 isoform caused birth defects in mice, reminiscent of those found in del22q11 patients, and genetic data in mouse, fish and human indicate that VEGF is a modifier of cardiovascular birth defect in the del 22q11 syndrome.
Journal ArticleDOI
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.
Sara Van de Veire,Ingeborg Stalmans,Femke Heindryckx,Hajimu Oura,Annemilaï Tijeras-Raballand,Thomas Schmidt,Sonja Loges,Imke Albrecht,Bart Jonckx,Stefan Vinckier,Christophe Van Steenkiste,Sonia Tugues,Sonia Tugues,Charlotte Rolny,Maria De Mol,Daniela Dettori,Patricia Hainaud,Lieve Coenegrachts,Jean Olivier Contreres,Tine Van Bergen,Henar Cuervo,Wei Hong Xiao,Carole Le Henaff,Ian Buysschaert,Behzad Kharabi Masouleh,Anja Geerts,Tibor Schomber,Philippe Bonnin,Vincent Lambert,Jurgen Haustraete,Serena Zacchigna,Jean-Marie Rakic,Wladimiro Jiménez,Agnès Noël,Mauro Giacca,Isabelle Colle,Jean-Michel Foidart,Gérard Tobelem,Manuel Morales-Ruiz,José Vilar,Patrick H. Maxwell,Stanley A. Vinores,Stanley A. Vinores,Geert Carmeliet,Mieke Dewerchin,Lena Claesson-Welsh,Evelyne Dupuy,Hans Van Vlierberghe,Gerhard Christofori,Massimiliano Mazzone,Michael Detmar,Desire Collen,Peter Carmeliet +52 more
TL;DR: It is shown that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease and warrant further testing of anti-PlGF therapies.
Journal ArticleDOI
Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy.
Matthew B. Schlenker,Husayn Gulamhusein,Ina Conrad-Hengerer,Alix Somers,Markus Lenzhofer,Ingeborg Stalmans,Herbert A. Reitsamer,Fritz H. Hengerer,Iqbal Ike K. Ahmed +8 more
TL;DR: There was no detectable difference in risk of failure and safety profiles between standalone ab interno microstent with M MC and trabeculectomy with MMC.